Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 10/20 | 0.77 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17632871 | 1.00 | USP30 (0.77) | USP30LRRK2ABL1MAP4K1 | |
| SCHEMBL17631918 | 0.88 | USP30 (0.61) | USP30 | |
| SCHEMBL17631914 | 0.88 | USP30 (0.61) | USP30 | |
| SCHEMBL20031287 | 0.87 | USP30 (1.00) | USP30 | |
| SCHEMBL17631656 | 0.86 | USP30 (0.58) | USP30LRRK2ABL1 | |
| SCHEMBL17631651 | 0.86 | USP30 (0.58) | USP30LRRK2ABL1 | |
| SCHEMBL17632652 | 0.83 | USP30 (0.55) | USP30 | |
| SCHEMBL17632655 | 0.83 | USP30 (0.55) | USP30 | |
| SCHEMBL17632452 | 0.83 | USP30 (0.64) | USP30LRRK2ABL1 | |
| SCHEMBL19281688 | 0.83 | USP30 (0.64) | USP30LRRK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3828179-A1 | CYANOPYRROLIDINES AS DUB MODULATORS | Mission Therapeutics Limited (GB) | 2021-06-02 | — | — | EP | claimed |
| EP-3197883-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-03-18 | — | — | EP | claimed |
| US-10392380-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2019-08-27 | — | — | US | claimed |
| US-20180162852-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED | 2018-06-14 | — | — | US | claimed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | claimed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | claimed |
| EP-3197883-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2017-08-02 | — | — | EP | claimed |
| WO-2016046530-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2016-03-31 | — | — | WO | claimed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11472798-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2022-10-18 | — | — | US | disclosed |
| EP-3828179-A1 | CYANOPYRROLIDINES AS DUB MODULATORS | Mission Therapeutics Limited (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-20200369658-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-11-26 | — | — | US | disclosed |
| US-10774078-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2020-09-15 | — | — | US | disclosed |
| US-10392380-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-20180162852-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LIMITED | 2018-06-14 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| EP-3197883-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046530-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774078-B2 | Compounds | UCHL1, UCHL3, UCHL5 | USP30 20/4885LRRK2 419/4885ABL1 223/4885 |
| US-11472798-B2 | Compounds | UCHL1, UCHL3, UCHL5 | USP30 20/4885LRRK2 419/4885ABL1 223/4885 |
| US-20180162852-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | USP30 19/4885LRRK2 479/4885ABL1 291/4885 |
| US-10392380-B2 | Compounds | UCHL1, UCHL3, UCHL5 | USP30 20/4885LRRK2 419/4885ABL1 223/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | USP30 20/4885LRRK2 419/4885ABL1 223/4885 |
| US-20200369658-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | USP30 19/4885LRRK2 479/4885ABL1 291/4885 |
| US-20170247365-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | USP30 19/4885LRRK2 479/4885ABL1 291/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | USP30 19/4885LRRK2 479/4885ABL1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.